PTO-1449 REPRODUCED

INFORMATION DISCLOSURE SITATION IN AN APPLICATION

(Use several sheets if necessary)

APR 2 4 2002 April 18, 2002

ATTORNEY DOCKET NO. 2685.2030-000

APPLICANTS Schmitke, et al.

FILING DATE June 22, 2001 GROUP 1619 1616

APPLICATION NO.

09/888,126

RADENS. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLAS	s	FILING DATE II APPROPI IATE
M	AA	4,161,516	07/17/79	Bell	424	14		
1	AB	4,272,398	06/09/81	Jaffe	252	316	HD31	
	AC	4,590,206	05/20/86	Forrester, et al.	514	456	HC	APR
	AD	4,741,872	05/03/88	De Luca, et al.	264	4.7	CENTER	Ž 2
	AE	4,818,542	04/04/89	De Luca, et al.	424	491	7	υī
	AF	4,855,144	08/08/89	Leong, et al.	424	487	1600/2900	002
	AG	4,857,311	08/15/89	Domb, et al.	424	78		
	АН	4,865,789	09/12/89	Castro, et al.	264	122		
	AI	4,904,479	02/27/90	Illum	424	490		
1	AJ	5,069,936	12/03/91	Yen	427	213.33		
	AK	5,145,684	09/08/92	Liversidge, et al.	424	489		
	AA2	5,160,745	11/03/92	De Luca, et al.	424	487		
	AB2	5,169,871	12/08/92	Hughes, et al.	521	64		
	AC2	5,384,133	01/24/95	Boyes, et al.	424	501		
	AD2	5,456,917	10/10/95	Wise, et al.	424	426		
1	AE2	5,607,695	03/04/97	Ek, et al.	424	468		
	AF2	5,612,053	03/18/97	Baichwal, et al.	424	440		
	AG2	5,260,306	11/09/93	Boardman, et al.	514	291		
	AH2	5,690,954	11/25/97	Illum	424	434		
	AI2	5,707,644	01/13/98	Illum	424	434		
	AJ2	5,804,212	09/08/98	Illum	424	434		
	AK2	5,064,650	11/12/91	Lew	424	435		
	ааз	5,075,109	12/24/91	Tice, et al.	424	88		
	AB3	5,100,669	3/31/92	Hyon, et al.	424	426		
	AC3	2,470,296	05/17/49	Fields	128	266		
	AD3	2,533,065	12/05/50	Taplin, et al.	167	65		
	AE3	2,992,645	07/18/61	Fowler	128	208		
	AF3	3,781,230	12/25/73	Vassiliades, et al.	260	2.5	_	
V	AG3	3,957,965	05/18/76	Hartley, et al.	424	14		

(1996).Ganderton, D., "The Generation of Respirable Clouds Form Coarse Powder Aggregates," J. Biopharmaceutical Sciences, 3(1/2):101-105 (1992). Gehr, P. et al., "Surfactant and Inhaled Particles in the Conducting Airways: AU2 Structural, Stereological, and Biophysical Aspects," Microscopy Res. And Tech., 26:423-436 (1993). Gerrity, T.R., et al., "Calculated Deposition of Inhaled Particles in the AV2 Airway Generations of Normal Subjects," J. Appl. Phys., 47(4):867-873 (1979). Morén, F., "Aerosol Dosage Forms and Formulations," in Aerosols in Medicine. AW2 Principles, Diagnosis and Therapy, Morén, et al., Eds, Elsevier, Amsterdam, 1985. Morimoto, Y., and Adachi, Y., "Pulmonary Uptake of Liposomal AX2 Phosphatidylcholine Upon Intratracheal Administration to Rats," Chem. Pharm. Bull. 30(6):2248-2251 (1982). AY2 Mulligan, R.C., "The Basic Science of Gene Therapy", Science, 260:926-932 (1993). DATE CONSIDERED 3/4/03M. Haghighate EXAMINER

<u> </u>	eU)	e several sheets if necessary)						
		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
M	AZ2	Mumenthaler, M., et al., "Feasibility Study on Spray-Drying Protein Pharmaceuticals: Recombinant human Growth Hormone and Tissue-Type Plasminogen Activator," Pharm. Res., 11(1):12-20 (1994).						
	AR3	Niven, R.W., et al., "The Pulmonary Absorption of Aerosolized and Intratracheally Instilled rhG-CSF and monoPEGylated rhG-CSF," Pharm. Res., 12(9):1343-1349 (1995).						
	AS3	Okumura, K., et al., "Intratracheal Delivery of Insulin. Absorption from Solution and Aerosol by Rat Lung," Int. J. Pharmaceutics, 88:63-73 (1992).						
	АТЗ	Patton, J.S., and R.M. Platz, "(D) Routes of Delivery: Case Studies (2) Pulmonary Delivery of Peptides and Proteins for Systemic Action", Adv. Drug Del. Rev., 8:179-196 (1992).						
	AU3	Patton, J.S., et al., "Bioavailability of pulmonary delivered peptides and proteins: α -interferon, calcitonins and parathyriod hormones," J. Controlled Release, 28:79-85 (1994).						
	AV3	Pavia, D., "Lung Mucociliary Clearance". In Aerosols and the Lung: Clinical and Experimental Aspects, Clarke, S.W. and Pavia, D., eds. (Butterworths, London), pp. 127-155, (1984).						
	AW3	Landahl, "On The Removal of Air-borne Droplets by The Human Respiratory Tract: I. The Lung," Bull. Math. Biophys., 12:43-56 (1950).						
	AX3	Timsina, M.P., et al., "Drug Delivery to the Respiratory Tract Using Dry Powder Inhalers," Int. J. of Pharm., 101:1-13 (1994).						
	AY3	Adjei, A., and Garren, J., "Pulmonary Delivery of Peptide Drugs: Effect of Particle Size on Bioavailability of Leuprolide Acetate in Healthy Male Volunteers," Pharm. Res., 7(6):565-569 (1990).						
	AZ3	Altshuler, B., et al., "Aerosol Deposition in the Human Respiratory Tract," Am. Med. Assoc. Arch. of Indust. Health 15:293-303 (1957).						
	AR4	Anderson, P.J., et al., "Effect of Cystic Fibrosis on Inhaled Aerosol Boluses," Am. Rev. Respir. Dis., 140:1317-1324 (1989).						
	AS4	Pinkerton, K.E., et al., "Aerosolized Fluorescent Microspheres Detected in the Lung Using Confocal Scanning Laser Microscopy", Microscopy Res. and Tech., 26:437-443 (1993).						
	AT4	Colthorpe, P., et al., "The Pharmacokinetics of Pulmonary-Delivered Insulin: A Comparison of Intratracheal and Aerosol Administration to the Rabbit," Pharm. Res. 9(6):764-768 (1992).						
	AU4	Rudt, S., and R.H. Muller, "In Vitro Phagocytosis Assay of Nano- and Microparticles by Chemiluminescence. I. Effect of Analytical Parameters, Particle Size and Particle Concentration," J. Contr. Rel., 22:263-271 (1992).						
V	AV4	Rudt, S., et al., "In Vitro Phagocytosis Assay of Nano- and Microparticles by Chemiluminescence. IV. Effect of Surface Modification by Coating of Particles with Poloxamine and Antarox CO on the Phagocytic Uptake", J. of Contr. Rel. 25:123-132 (1993).						
II								

M. Haghighatian

DATE CONSIDERED

3/4/03

JOC 12		err besiteop (esisi, iaie.					
PTO-14	49 REP	PRODUCED	OIPE	ATTORNEY DOCKET NO. 2685.2030-000	APPLICATI 09/888		
		ORMATION DISCLOSURE (IN AN APPLICATION	CITATION	Senmitke, et al.	•		
	(Us	April 18, 2002 e several sheets if nec	APR 2 4 200	FIGURE DATE FIGURE 22, 2001	GROUP 1619 /	616	
			FREEZINS	ATENT DOCUMENTS	<u>L </u>		
_	1	****				SUB-	TRANSLATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS	YES NO
m	AL	EP 0 257 915	02 MAR 88	EPO			
	AM	EP 0 335 133	04 OCT 89	EPO	W		
	AN	WO 91/04732	18 APR 91	PCT			
	AO	WO 94/04133	03 MAR 94	PCT			
	AP	WO 96/23485	08 AUG 96	PCT			
	AQ	WO 99/16419	08 APR 99	PCT			
	AL2	WO 99/16420	08 APR 99	PCT	:		
	AM2	WO 99/16421	08 APR 99	PCT			
	AN2	WO 99/16422	08 APR 99	PCT			
V	A02	EP 0 072 046	16 FEB 83	EPO			
		OTHER DOCUMENT	S (Including Author	or, Title, Date, Pertinent Pa	ages, Etc.)	
M	AW4	Ruffin, R.E., et Propranolol in As	al., "The Prefe thmatic Patien	erential Deposition of ts," Chest 80(6):904-90	Inhaled 7 (1981)	Isoprot	erenol and
	AX4	Sela, M., et al., (1956).	"Multichain Po	olyamino Acids," J. Am.	Chem.	Soc., 7	8:746-751
	AY4			Delivery Systems for E arm. Res. 10(4):487-496			
	AZ4			Conduit or Collector f ivery IV, 187-195 (1994		maceutic	al
	AR5	Tabata, Y., and Y Phagocytosis," J.	. Ikada, "Effe of Colloid and	ct of Surface Wettabili d Interface Sci., 127(1	ty of Mi.):132-14	icrosphe 10 (1989	res on
	AS5	Tabata, Y., and Y Microspheres Comp of Biomed. Mater.	osed of L-lact:	ophage Phagocytosis of ic Acid/glycolic Acid H 858 (1988).	Biodegra Iomo- and	adable i Copoly	mers," J.
	AT5	Tabata, Y., and I Microspheres on T 22:356-362(1988).	heir Phagocyto	ect of Size and Surfaces is by Macrophage," J .	Charge Biomed.	of Poly Mater.	mer Res.,
	AU5	Allen, T.M., et a with the Intraven Biophys. Acta. 11	ous and Intrap	ous Administration of I eritoneal Routes of Inj	iposomes ection,	s: A Com	mparison em. et
	AV5		olymer: Poly(la	is and RGD Peptide Modi actic acid-co-lysine),"			
EXAMI	NER //	n. Haghigha	the	DATE CONSIDERED 3/4/	03		

DO	C II) NO.:	@PFDesktop\::ODMA/MHODiManage;254597;	1	Sheet 5 of 13
PT	0-144	9 REPROD	DUCED DRMATION DISCLOSURE CITATION	ATTORNEY DOCKET NO. 2685.2030-000	APPLICATION NO. 09/888,126
		INFO	IN AN APPLICATION	APPLICANTS Schmitke, et al.	
		(IIa	April 18, 2002 WW 17 ddy and a several sheets if necessary)	FILING DATE June 22, 2001	GROUP 1619 6/6
			OTHER DOCUMENTS (Including Autho	<u> </u>	
-	M	AW5	Tansey, I.P., "The Challenges i Aerosols Using Ozone-Friendly P (1994).	n the Development of Me	tered Dose Inhalation
,)	AX5	Turner, J.R., and S.V. Hering, Impaction Surfaces," J. Aerosol	"Greased and Oiled Subs Sci., 18(2):215-224 (1	trates as Bounce-Free 987).
		AY5	Lai, Y-L., et al., "Sustained B Poly(Glycolide-co-Lactide) Micr	ronchodilation with Isc ospheres," Pharm. Res.,	proterenol 10(1):119-125 (1993).
		AZ5	Visser, J., "An Invited Review: Affecting Power Fludization," P	Van der Waals and Othe owder Technology, 58:1-	r Cohesive Forces 10 (1989).
		AR6	Wall, D.A., "Pulmonary Absorpti 2:1-20 (1995).	on of Peptides and Prot	eins," Drug Delivery,
		AS6	Warheit, D.B., and Hartsky, M.A Phagocytosis in Pulmonary Clear Rodent Species," Microscopy Res	ance to Inhaled Particl	es: Comparisons Among
		AT6	Langer, R., "New Methods of Dru	g Delivery", <i>Science</i> , 2	49:1527-1533 (1990).
		AU6	Wong, M., and Suslick, K.S., "S Microbubbles," Mat. Res. Soc. S		
		AV6	Zanen, P., et al., "The Optimal Mild Asthmatics", Int. J. of Ph	Particle Size for β-acarm., 107:211-217 (1994	drenergic Aerosols in
		AW6	Zanen, P., et al., "The Optimal in Mild Asthmatics", Int. J. of	Particle Size for Para Pharm., 114:111-115 (1	sympathicolytic Aerosols 995).
		AX6	Zeng, X.M., et al., "The Contro Pharm., 124:149-164 (1995).	lled Delivery of Drugs	to the Lung," Int. J. of
		AY6	Kohler, D., "Aerosols for Syste	mic Treatment" Lung, Su	ppl: pp. 677-684 (1990).
		AZ6	Anderson, M., et al., "Human De Inhaled with an Extremely Low F	position and Clearance low Rate," <i>Exp. Lung Re</i>	of 6-µm Particles es., 21:187-195 (1995).
		AR7	Beck, L.R., et al., "A New Long Administration of Progesterone, (1979).	-Acting Injectable Micr " Fertility and Sterili	cocapsule System for the ty, 31(5):545-551
		AS7	Brown, A.R., et al ., "Propellan Potential Therapeutic Agents in $28:241-257$ (1994).		
		AT7	Carroll, B.A., et al., "Gelatin Ultrasonic Contrast Agents," In	Encapsulated Nitrogen vestigative Radiology,	Microbubbles as 15:260-266 (1980).
		AU7	Carroll, B.A., et al., "Ultraso Encapsulated Microbubbles," Rad	nic Contrast Enhancemen iology, 143:747-750 (19	t of Tissue by (82).
		AV7	Ch'ng, H.S., et al., "Bioadhesi Drug Delivery II: Synthesis and Bioadhesive Polymers," J. of Ph	Evaluation of Some Swe	lling, Water-Insoluble
•	V	AW7	Clark, A., and P. Byron, "Depen		

EXAMINER M. Hagheghatian

DATE CONSIDERED 3/4/03

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

April 18, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 2685.2030-000 APPLICANTS

APPLICATION NO. 09/888,126

Mithe, et al.

FILE DATE Just 22, 2001 GROUP 1619-1616

			0.5.	PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES 1
N F	АН3	4,009,280	02/22/77	Macarthur, et al.	424	283	
1 7	AI3	4,089,800	05/16/78	Temple	252	316	
I	AJ3	4,173,488	11/06/79	Vassiliades, et al.	106	213	<u>E</u>
1	АКЗ	4,352,883	10/05/82	Lim	435	178	
I	AA4	4,391,909	07/05/83	Lim	435	178	APR & S
7	AB4	4,466,442	08/21/84	Hilmann, et al.	128	653	5 2682 1800/
7	AC4	4,524,769	06/25/85	Wetterlin	128	203.15	1800/2900
	AD4	4,572,203	02/25/86	Feinstein	128	661	8
7	AE4	4,615,697	10/07/86	Robinson	604	890	
I	AF4	4,679,555	07/14/87	Sackner	128	203.15	
7	AG4	4,743,545	05/10/88	Torobin	435	41	
7	AH4	4,774,958	10/04/88	Feinstein	128	660.01	
I	AI4	4,789,550	12/06/88	Hommel, et al.	424	493	
T I	AJ4	4,847,091	07/11/89	Illum	424	455	
1 2	AK4	4,861,627	08/29/89	Mathiowitz, et al.	427	213.31	
7	AA5	4,917,119	04/17/90	Potter, et al.	131	273	
I	AB5	4,976,968	12/11/90	Steiner	424	491	
I	AC5	4,994,281	02/19/91	Muranishi, et al.	424	497	
1	AD5	5,033,463	07/23/91	Cocozza	128	203.21	
1	AE5	5,123,414	06/23/92	Unger	128	654	
1	AF5	5,195,520	03/23/93	Schlief, et al.	128	660.02	
1	AG5	5,204,108	04/20/93	Illum	424	434	
I	AH5	5,204,113	04/20/93	Hartley, et al.	424	45	
1	AI5	5,271,961	12/21/93	Mathiowitz, et al.	427	213.31	
7	AJ5	5,327,883	07/12/94	Williams, et al.	128	203.12	
7	AK5	5,334,381	08/02/94	Unger	424	9	
1 1	AA6	5,352,435	10/04/94	Unger	424	9	
1 2	AB6	5,393,524	02/28/95	Quay	424	9	
1/1.	AC6	5,407,609	04/18/95	Tice, et al.	264	46	

BEC⊏IVED

				ATTORNEY DOCKET NO. 2685.2030-000	APPLICATION NO. 09/888,126				
	INFO	RMATION DISCLOSURE C IN AN APPLICATION	ITATION	Applicants	<u> </u>				
			APR 2 LUM	Schmitke, et al.					
	(İI.a.a	April 18, 2002		TLING DATE June 22, 2001	GROUP	1616			
		several sheets it hece		ATENT DOCUMENTS	<u></u>				
						SUB-CLASS	TRANSI	ATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	МО	
m	AD6	5,482,946	01/09/96	Clark, et al.	514	291			
1	AE6	5,518,709	05/21/96	Sutton, et al.	424	9.52	EC.	25	
	AF6	5,306,483	04/26/94	Mautone	424	45	CH CENTER 1600/2900	AP	
	AG6	5,795,594	08/18/98	York, et al.	424	489	NE	₹ 2	
	AH6	5,851,453	12/22/98	Hanna, et al.	264	5	R 16	5 21	
	AI6	6,063,138	05/16/00	Hanna, et al.	23	295R	82	2002	
	AJ6	5,855,913	01/05/99	Hanes, et al.	424	489	8		
	AK6	5,874,064	02/23/99	Edwards, et al.	424	46			
	AA7	5,985,309	11/16/99	Edwards, et al.	424	426		, i	
	AB7	6,136,295	10/24/00	Edwards, et al.	424	45			
	AC7	US RE37,053 E	02/13/01	Hanes, et al.	424	489			
	AD7	4,069,819	24 JAN 98	Valentini, et al.	128	206			
	AE7	5,997,848	12/07/99	Patton, et al.	424	46			
	AF7	5,486,569	01/23/96	Henderson, et al.	525	116	<u> </u>		
			FOREIGN	PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLA	SUB- CLASS	TRANSLATION YES NO		
M	AP2	0 213 303	04 SEP 91	EPO					
٦	AQ2	0 324 938	26 JUL 89	EPO					
	AL3	0 458 745	14 MAY 91	EPO					
	АМЗ	1 288 583	17 NOV 69	GB					
	AN3	WO 80/02365	13 NOV 80	PCT					
	A03	WO 88/04556	30 JUN 88	PCT					
	АРЗ	WO 88/09163	01 DEC 88	PCT					
	AQ3	WO 91/06287	16 MAY 91	PCT					
	AL4	WO 91/06286	16 MAY 91	PCT					
V	AM4	WO 91/12823	05 SEP 91	PCT					
EXAMINER M. Haghighation			DATE CONSIDERED 3/4	1/03					

PT	0-14	49 REPRO	OIPE ATTORNEY DOCKET NO.	APPLICATION NO. 09/888,126	2	PR			
		INFO	DRMATION DISCLOSURE CITATION IN AN APPLICATION APPLICATION	09/000/120	ENTER 1600/2900	2 5 2002			
			April 18, 2002 April 18, 2002 Eding Date April 22, 2001	GROUP	<u>8</u>	₹			
		(Us	e several sheets if necessary	1619/6/6	<u>s</u>				
			OTHER DOCUMENTS (Including Author, Title, Date, Pertinent	Pages, Etc.)					
1	N	AW9	Newman, S.P., "Therapeutic Inhalation Agents and Devic 76(5):194-207 (1984).	es," Inhalation T	herap —	у,			
		AX9	Newman, S.P., "Aerosol Deposition Considerations in In Chest, 88(2):152S-160S (1985).	halation Therapy,	"				
		AY9		New, R.R.C., "Characterization of Liposomes," in Liposomes: A Practical Approach, R. New, Editor, IRL Press, New York, 105-161 (1990).					
		AZ9	Niven, R.W., et al., "Solute Absorption From the Airwa Lung. III. Absorption of Several Peptidase-Resistant, Poly-(2-Hydroxyethyl)-Aspartamides," Pharm. Res., 7(10	Synthetic Polypep	tides	: } :			
		AR10	Niwa, T., et al., "Aerosolization of Lactide/Glycolide Nanospheres for Pulmonary Delivery of Peptide-Drugs," 115(9):732-741 (1995).						
		AS10	Ogiwara, M., "Clearance and Maximum Removal Rate of Lip Impaired Liver of Rat," Gastroenterologia Japonica, 19						
		AT10	Smith, A.L., and B. Ramsey, "Aerosol Administration of Respiration, 62(suppl 1):19-24 (1995).	Antibiotics,"					
		AU10	Smith, P.L., "Peptide Delivery via the Pulmonary Route Local and Systemic Delivery," J. of Contr. Rel., 46:99		h for	.			
		AV10	Strand, S.E., and L. Bergqvist, "Radiolabeled Colloids the Lymphatic System," Critical Reviews in Therapeutic 6(3):211-238 (1989)	and Macromolecul Drug Carrier Sys	es in tems,	ι			
		AW10	Blackett, P.M., and G. Buckton, "A Microcalorimetric I Interaction of Surfactants with Crystalline and Partia Salbutamol Sulphate in a Model Inhalation Aerosol Syst Research, 12(11):1689-1693 (1995).	lly Crystalline					
		AX10	Brain, J.D., "Physiology and Pathophysiology of Pulmon The Reticuloendothelial System, Reichard and Filkins, York), pp. 315-327 (1985).			:W			
		AY10	Byron, P.R., "Determinants of Drug and Polypeptide Bio Aerosols Delivered to the Lung," Adv. Drug. Del. Rev.,						
		AZ10	Clark, A.R., and M. Egan, "Modelling the Deposition of Aerosols," J. Aerosol Sci., 25(1):175-186 (1994).	Inhaled Powdered	Drug	Γ			
		AR11	Le Corre, P., et al., "Preparation and Characterizatio Polylactide and Polylactide-Co-Glycolide Microspheres, Pharmaceutics, 107:41-49 (1994).		Loade	:d			
		AS11	Leone-Bay, A., et al., "Microsphere Formation in a Ser Amino Acids: Properties, Molecular Modeling, and Oral calcitonin," J. of Med. Chem., 38(21):4257-4262 (1995)	Delivery of Salmo	dα- n				
		AT11	Liu, F., et al., "Pulmonary Delivery of Free and Lipos Res. $10(2):228-232$ (1993).	omal Insulin," Ph	arm.				
١	1	AU11	Liu, W.R., et al., "Moisture-Induced Aggregation of Ly the Solid State," Biotechnol. and Bioeng., 37:177-184	ophilized Protein (1991).	s in				
EX	AMI	NER /	n Hallia of DATE CONSIDERED	>					

APPLICATION NO. PTO-1449 REPRODUCED ATTORNEY DOCKET NO. OIPE 09/888,126 2685.2030-000 INFORMATION DISCLOSURE CITATION ADALICANTS APR 2 4 2002 Schmitke, et al. IN AN APPLICATION April 18, 2002 FAING DATE GROUP (Use several sheets if necessary 1619/6/6 **S**une 22, 2001 FOREIGN PATENT DOCUMENTS SUB-TRANSLATION DOCUMENT NUMBER COUNTRY CLASS CLASS YES DATE NO M AN4 WO 92/18164 29 OCT 92 PCT A04 10 DEC 92 PCT WO 92/21382 mi AP4 WO 93/25221 23 DEC 93 PCT A04 WO 94/08627 28 APR 94 PCT AL5 WO 94/16739 04 AUG 94 PCT AM5 WO 96/15814 30 MAY 96 PCT WO 97/36574 AN5 09 OCT 97 PCT A05 0 510 731 A1 28 OCT 92 EPO AP5 WO 95/35097 28 DEC 95 PCT A05 0 656 206 A1 07 JUN 95 EPO AL6 **EPO** 0 634 166 A1 18 JAN 95 AM6 WO 94/07514 14 APR 94 PCT AN₆ WO 95/00127 05 JAN 95 PCT A06 WO 95/24183 14 SEP 95 PCT AP6 WO 95/07072 16 MAR 95 PCT AQ6 WO 96/09814 PCT 04 APR 96 AL7 WO 97/36574 09 OCT 97 PCT AM7 0 257 956 B1 20 MAY 92 EPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) AV11 Martonen, T.B., "Mathematical Model for the Selective Deposition of Inhaled M Pharmaceuticals", J. of Pharm. Sci., 82(12):1191-1198 (1993). AW11 Masinde, L.E., and Hickey, A.J., "Aerosolized Aqueous Suspensions of Poly(L-Lactic Acid) Microspheres," Int. J. of Pharmaceutics, 100:123-131 (1993). AX11 Mathiowitz, E., et al., "Novel Microcapsules for Delivery Systems," Reactive Polymers, 6:275-283 (1987). Mathiowitz, E., et al., "Polyanhydride Microspheres. IV. Morphology and AY11 Characterization of Systems Made by Spray Drying, " J. of Appl. Polymer Sci. 45:125-134 (1992). AZ11 Mathiowitz, E., et al., "Morphology of Polyanhydride Microsphere Delivery Systems, " Scanning Microscopy, 4(2):329-340 (1990). Mathiowitz, E., and R. Langer, "Polyanhydride Microspheres as Drug Carriers I. Hot-Melt Microencapsulation," J. of Controlled Release 5:13-22 (1987). AR12 DATE CONSIDERED EXAMINER 3/4/03

PTO-1	449 REPR	DDUCED	OIPE	ATTORNEY DOCKET NO. 2685.2030-000	APPLICAT			
		RMATION DISCLOSURE CO IN AN APPLICATION	TATION	APALICANTS Schmitke, et al.				
	(Use	April 18, 2002 several sheets if nece	APR 2 4 201	Figure Date	GROUP 1619	616		
			RABENA	PATENT DOCUMENTS	<u> </u>			
EXA M- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	I	G DATE F PRIATE
m	AG7	6,077,543	06/20/00	Gordon, et al.	424	489	_	
	АН7	5,997,848	12/07/99	Patton, et al.	424	46	오	
	AI7	5,466,841	11/14/98	Horrobin, et al.	554	79	CEN	APR
	AJ7	5,902,802	05/11/99	Heath	514	76	TER.	25
	AK7	4,480,041	10/30/84	Myles, et al.	436	508	1600/2900	2002
	AA8	5,994,314	11/30/99	Eljamal, et al.	514	44	0/29))
1	AB8	5,698,721	12/16/97	Heath	554	80	8	
			FOREIG	N PATENT DOCUMENTS		•		
i		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSI YES	LATION NO
M	AN7	1,300,009	05 MAY 92	Canada				
1	A07	1,302,258	02 JUN 92	Canada				
	AP7	2,058,428	05 SEP 00	Canada				<u> </u>
	AQ7	2,085,884	30 DEC 91	Canada				
	AL8	2,111,002	22 AUG 00	Canada				
	AM8	2,126,244	26 SEP 00	Canada				
V	AN8	2,170,394	02 MAR 95	Canada				
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)		
W	AS12			anhydride Microspheres as Removal," J. of Appl. Po				74
	AT12	Davies, et al., " Physiol. 32(5):59	_	half-micron aerosols. I.	. Experi	mental,"	J. Aj	ppl.
	AU12			on of 5-15 μ m Diameter Alzation Technique," Pharm				
	AV12		," in Critic	very of Therapeutic and I al Reviews in Therapeutic				
	AW12	Gonda, I., "Prefa Therapeutic and D Rev. 5:1-9 (1990)	iagnostic Ag	sues and Future Prospects ents to the Respiratory T	in the	Deliver Adv. Dru	y of g Del	•
	AX12	Pharmaceutical Sc	<u>iences</u> 1991,	Principles in Aerosol Del Crommelin, D.J. and K.K. art, pp. 95-117 (1992).	livery," Midha,	in <u>Topi</u> Eds., N	cs in ledpha	rm
EXAM	INER	n. Haghia	hatian	DATE CONSIDERED 3/4/0	3			

DOC ID	NO.:	@PFDesktop\::ODMA/MHO	DMA/iManage;254	597;1		She	et 12 c	f 13
PTO-144	9 REPROI	DUCED	OIPE	ATTORNEY DOCKET NO. 2685.2030-000	APPLICAT			
	INFOR	MATION DISCLOSURE CA IN AN APPLICATION	TATION C	APPLICANTS chmitke, et al.		<u> </u>		
		April 18, 2002	, ΑΓΚ 2 4 20U2 Ά	3	anoven .			
	(Use	several sheets if nece	**************************************	June 22, 2001	GROUP 1619	616		
			ALLE MAN	PATENT DOCUMENTS				,
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILI DATE APPRO TE	IF PRIA
M	AC8	5,830,853	11/03/98	Bäckström, et al.	514	4		
<u> </u>	AD8	5,814,607	09/29/98	Patton	514	12	5	
	AE8	5,518,998	05/21/96	Bäckström, et al.	514	3	<u>R</u>	APH
	AF8	5,551,489	09/03/96	Trofast et al.	141	18	1	20
-	AG8	6,231,851 B1	05/15/01	Platz et al.	424	85.6	5	5 2
	8НА	6,221,338 B1	04/24/01	Staniforth	424	45	1600/2900	2002
	AI8	6,123,936	09/26/00	Platz et al.	424	85.6	8	
	AJ8	6,027,714	02/22/00	Trofast	424	45		
	AK8	5,980,949	11/09/99	Trofast	424	489		
\top	AA9	5,934,273	08/10/99	Andersson et al.	128	203.12		
	AB9	5,911,941	06/15/99	Rokhvarger et al.	264	432		
	AC9	5,804,217	09/08/98	Björk et al.	424	488		
	AD9	5,648,101	07/15/97	Tawashi	424	718		
	AE9	5,642,728	07/01/97	Andersson et al.	128	203.15		
	AF9	5,603,945	02/18/97	Isobe et al.	424	442		
	AG9	5,514,754	05/07/96	Henderson et al.	525	296		
V	АН9	5,506,203	04/09/96	Bäckström et al.	514	4	<u> </u>	
		OTHER DOCUMENTS	(Including Au	thor, Title, Date, Pertinent	Pages,	Etc.)	·····	
m	AY12	Gonda, I., "Targo Technology (ed. 7	eting by Depo A.J. Hickey)	osition," in Pharmaceutic , Marcel Dekkar Inc., pp.	al Inha: 61-82,	lation Ae: New York	rsol (1992).
	AZ12	Heyder, J., et a. the Size Range 0	1., "Deposit .005-15 μm,"	ion of Particles in the H J. Aerosol. Sci., 17(3):	uman Res 811-825	spiratory (1996).	Tract	in
	AR13			Mathematical models of pa Aerosol Sci., 15:697-707			n in t	he
	AS13			eposition of Aerosol Part nd Mouth Breathing," J. A				
J	AT13	Hickey, A.J., et Drugs from Dry Po (1992).	al., "Use o owder Aeroso	f Particle Morphology to ls," J. Biopharmaceutical	Influence Sci., 3	ce the De	livery 113	of
EXAMII	NER /	n. Haghigh	atm	DATE CONSIDERED 3/4/8	3			

AS14 Kobayashi, S. et al., "Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats," Pharm. Res., 13(1):80-83 (1996). Komada, F. et al., Intratracheal Delivery of Peptide and Protein Agents: AT14 Absorption from Solution and Dry Powder by Rat Lung," J. Pharm. Sci., 83(6): 863-867 (June, 1994). AU14 Krenis, L.J. and B. Strauss, "Effect of Size and Concentration of Latex Particles on Respiration of Human Blood Leucocytes," Proc. Soc. Exp. Med., 107: 748-750 (1961). AV14 Edwards, et al., "Large Porous Particles for Pulmonary Drug Delivery," Science, 276:1868-1871(1997). AW14 Heinemann, L., et al. "Time-action Profile of Inhaled Insulin," Diabet. Med., 14 (1): 63-72 (1997). AX14 Gietz, et al., "Sustained release of injectable zinc-recombinant hirudin suspend development and validation of in-vitro release model," Eur. J. Pharm. Biopharm, 45(3):259-264 (1998). AY14 Wang, et al., "Inhalation of Estradiol for Sustained Systemic Delivery," Journal of Aerosol Medicine, 12(1): 27-36 (1999). Krenis, L.J., et al., Effect of Size and Concentration of Latex Particles on AZ14 Respiration of Human Bloon Leucocytes," Department of Medicine, 107: 748-750 (1961).

EXAMINER

DATE CONSIDERED 3/4/03